Eagle Pharmaceuticals, Inc. Reports Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Eagle Pharmaceuticals, Inc. Reports Third Quarter 2015 Results
November 12, 2015 9:29 AM EST
Piper Jaffray reiterates an Overweight rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $97.00 (from $120.00), following the company's 3Q earnings report. Eagle reported EPS of ($0.65) on revenues of $6M, missing consensus on both. Analyst David Amsellem continues to believe there is optionality associated with Ryanodex in exertional heat stroke (EHS),... More
November 11, 2015 7:04 AM EST
Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of ($0.65), $0.09 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $5.07 million.
"Eagle has accomplished a great deal already this year, and we remain focused on achieving our goals in the particularly exciting and important final weeks ahead, said Scott Tarriff, President and Chief... More
